Tizanidine Tablet
Product Images NDC 55154-7287

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 55154-7287). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1.jpg (Figure 1)

Figure-1.jpg (Figure 1)
A line graph showing mean tizanidine concentration (ng/mL) over time (hours from dosing) for tizanidine tablets and capsules (2 x 4 mg) under fasted and fed conditions. The graph compares plasma concentrations across four scenarios: tablets with and without food, and capsules with and without food, depicting the pharmacokinetic profiles up to 24 hours post-dose.*
FDA Label Image

Figure-2.jpg (Figure 2)

Figure-2.jpg (Figure 2)
A line graph showing the mean change in muscle tone from baseline over 6 hours post-dose, measured by the Ashworth Scale. The graph compares three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo, illustrating the improvement in muscle tone with confidence intervals.*
FDA Label Image

Figure-3.jpg (Figure 3)

Figure-3.jpg (Figure 3)
A chart titled 'Seven Week Study—Mean Change in Muscle Tone 0.5 to 2.5 Hours After Dosing,' showing mean improvements measured by the Ashworth Scale with 95% confidence intervals. The graph compares tizanidine (mean dose 28.8 mg) and placebo groups at three timepoints: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint. Negative Ashworth scores indicate muscle tone improvement.*
FDA Label Image

Bag Label (Image 01)

Bag Label (Image 01)
Tizanidine tablets, USP 4 mg oral tablets, packaged as 10 tablets. The label includes instructions that it is not interchangeable with tizanidine capsules or Zanaflex capsules. Storage instructions specify controlled room temperature. Manufactured by Apotex Inc., Toronto, Canada, and Apotex Corp., Weston, Florida, distributed by Major Pharmaceuticals and Cardinal Health.*
FDA Label Image

Chemical-structure (Tizanidine Imtb 01)

Chemical-structure (Tizanidine Imtb 01)
Chemical structure of tizanidine hydrochloride, showing its heterocyclic rings, chlorine substituent, and hydrochloride salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.